Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2:45PM – 9/30/2014: Biotech in Israel @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

 

Real Time Media Conference Coverage  –  Business and Scientific Channels by: https://pharmaceuticalintelligence.com

Chaired by: 

• Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences

Panelists: 

• Orna Palgi, OticPharma

– Antianxiety

– Otic products

• Ora Bar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel

Office of Chief Scientist, support infrastructure at the State level,collaboration with big pharma,VC likfe Sciences, New idea HOw to have the life sciences to grow.

1,000 life sciences companies, very young, originates in Hospitals or Academia – out standing Science, development of markets and mentorship is in need of infusion  of directions

– Incubators in Israel – 20% and 80% by the Government

– Market in China, Joint venture, production in China – potential WIN-WIN

• Dan J. Gelvan, Managing Director, Life Sciences, Aurum Ventures MKI Ltd.

– drugs and pharmaceutical: Cancer, HF, Inflammatory

– early stage at university

– financial and fund raising in Israel, funnel large from Chief Scientist Office. Exit strategy, MedTech is for M&A, first stage comes from Israel

– opportunities with European companies

– Chinese come to Israel with big delegation looking for technologies that will bring progress in China

– Chinese perceive Western Medicine not to be ORAL but IV, if Oral no value for the Chinese

• Guy Goldberg, RedHill Biopharma

– Israeli-based US and European, Stock in Tel Aviva and US, license drugs globally,

Phase iii:

– Crohn’s Disease – multifactorial bacteria treated with a compound

– resistance to bacteria

– antiemetic – different mechanism of action – fungal base

how big Pharma perceive start up companies. JP Morgan more interested.Due diligence is done

Partnership in GI, start up seen as competition by Big Pharma that has Humira for Crohn’s Disease.

– synergy with US companies

Orbimed the largest Fund in Israel is majority investor in Otic Pharma

#pharmanews

@SachsAssociates@pharma_BI@BiotechNews